Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

· Issued by Arcutis Biotherapeutics, Inc.

On 6ix: 6ix.com/news/arcutis-announces-positive-results-from-integument-ped-pivotal-phase-3-trial-of

Watch Arcutis Biotherapeutics' latest callArcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call
Arcutis Biotherapeutics' next earnings callArcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings Call · Nov 4, 2026 at 4:30 PM ESTRegister
  • Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials
  • For the primary endpoint, 25.4% of children treated once daily with roflumilast cream 0.05% achieved Investigator Global Assessment (IGA) Success compared to 10.7% of children treated with vehicle (P

Arcutis Biotherapeutics, Inc. on 6ix

Story so far

Earlier from Arcutis Biotherapeutics

Later from Arcutis Biotherapeutics

All Arcutis Biotherapeutics news releases